{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:37:09Z","timestamp":1785800229389,"version":"3.56.0"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s10741-015-9500-0","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T08:54:45Z","timestamp":1438332885000},"page":"689-708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Fabry\u2019s disease: an example of cardiorenal syndrome type 5"],"prefix":"10.1007","volume":"20","author":[{"given":"Aashish","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.","family":"Zaragoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Faggiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Brocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Di Lullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,1]]},"reference":[{"key":"9500_CR1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.CCM.0000296264.41365.80","volume":"36","author":"O Dar","year":"2008","unstructured":"Dar O, Cowie MR (2008) Acute heart failure in the intensive care unit: epidemiology. Crit Care Med 36:S3\u2013S8","journal-title":"Crit Care Med"},{"key":"9500_CR2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ncpneph0673","volume":"3","author":"RW Schrier","year":"2007","unstructured":"Schrier RW (2007) Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 3:637","journal-title":"Nat Clin Pract Nephrol"},{"key":"9500_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/039139880803100101","volume":"31","author":"C Ronco","year":"2008","unstructured":"Ronco C (2008) Cardiorenal and renocardiac syndromes: clinical disorders in search of a systematic definition. Int J Artif Organs 31:1\u20132","journal-title":"Int J Artif Organs"},{"key":"9500_CR4","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1097\/01.CCM.0000296270.41256.5C","volume":"36","author":"KV Liang","year":"2008","unstructured":"Liang KV, Williams AW, Greene EL, Redfield MM (2008) Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 36:S75\u2013S88","journal-title":"Crit Care Med"},{"key":"9500_CR5","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00134-008-1017-8","volume":"34","author":"C Ronco","year":"2008","unstructured":"Ronco C, House AA, Haapio M (2008) Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 34:957\u2013962","journal-title":"Intensive Care Med"},{"key":"9500_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/eurheartj\/ehi020","volume":"26","author":"LG Bongartz","year":"2005","unstructured":"Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B (2005) The severe cardiorenal syndrome: \u2018Guyton revisited\u2019. Eur Heart J 26:11\u201317","journal-title":"Eur Heart J"},{"key":"9500_CR7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semnephrol.2005.09.003","volume":"26","author":"KJ Kelly","year":"2006","unstructured":"Kelly KJ (2006) Acute renal failure: much more than a kidney disease. Semin Nephrol 26:105\u2013113","journal-title":"Semin Nephrol"},{"key":"9500_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2215\/CJN.00730805","volume":"1","author":"T Berl","year":"2006","unstructured":"Berl T, Henrich W (2006) Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 1:8\u201318","journal-title":"Clin J Am Soc Nephrol"},{"key":"9500_CR9","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","volume":"52","author":"C Ronco","year":"2008","unstructured":"Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527\u20131539","journal-title":"J Am Coll Cardiol"},{"key":"9500_CR10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","volume":"31","author":"C Ronco","year":"2010","unstructured":"Ronco C, McCullough P, Anker SD et al (2010) Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31:703\u2013711","journal-title":"Eur Heart J"},{"key":"9500_CR11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0002-9343(98)00365-9","volume":"106","author":"BK Kramer","year":"1999","unstructured":"Kramer BK, Schweda F, Riegger GA (1999) Diuretic treatment and diuretic resistance in heart failure. Am J Med 106:90\u201396","journal-title":"Am J Med"},{"key":"9500_CR12","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.4049\/jimmunol.168.11.5817","volume":"168","author":"PN Cunningham","year":"2002","unstructured":"Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ (2002) Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 168:5817\u20135823","journal-title":"J Immunol"},{"key":"9500_CR13","doi-asserted-by":"crossref","first-page":"R1900","DOI":"10.1152\/ajpregu.00146.2006","volume":"292","author":"A Kumar","year":"2007","unstructured":"Kumar A, Paladugu B, Mensing J, Parrillo JE (2007) Nitric oxide-dependent and -independent mechanisms are involved in TNF-alpha -induced depression of cardiac myocyte contractility. Am J Physiol Regul Integr Comp Physiol 292:R1900\u2013R1906","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"9500_CR14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","volume":"10","author":"W Anderson","year":"1898","unstructured":"Anderson W (1898) A case of \u201cAngeio-keratoma\u201d. Br J Dermatol 10:113\u2013117","journal-title":"Br J Dermatol"},{"key":"9500_CR15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF01986897","volume":"43","author":"J Fabry","year":"1898","unstructured":"Fabry J (1898) Ein Beitrag zur Kenntnis der Purpura haemorragica nodularis (Purpura papulosa hemorrhagica Hebrae). Arch Dermatol Syphilol 43:187\u2013200","journal-title":"Arch Dermatol Syphilol"},{"key":"9500_CR16","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/S0021-9258(18)51888-3","volume":"238","author":"CC Sweeley","year":"1963","unstructured":"Sweeley CC, Klionsky B (1963) Fabry\u2019s disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 238:3148\u20133150","journal-title":"J Biol Chem"},{"key":"9500_CR17","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163\u20131167","journal-title":"N Engl J Med"},{"key":"9500_CR18","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/2271173b0","volume":"227","author":"JA Kint","year":"1970","unstructured":"Kint JA (1970) The enzyme defect in Fabry\u2019s disease. Nature 227:1173","journal-title":"Nature"},{"key":"9500_CR19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.1138375","volume":"189","author":"C Duve","year":"1975","unstructured":"Duve C (1975) Exploring cells with a centrifuge. Science 189:186\u2013194","journal-title":"Science"},{"key":"9500_CR20","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ (2001) Alpha-galactosidase a deficiency: fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733\u20133774"},{"key":"9500_CR21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0002-9378(90)90410-9","volume":"162","author":"S Popli","year":"1990","unstructured":"Popli S, Leehey DJ, Molnar ZV, Nawab ZM, Ing TS (1990) Demonstration of Fabry\u2019s disease deposits in placenta. Am J Obstet Gynecol 162:464\u2013465","journal-title":"Am J Obstet Gynecol"},{"key":"9500_CR22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","volume":"29","author":"AC Vedder","year":"2006","unstructured":"Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JM, Hollak CE (2006) Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 29:106\u2013111","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0016-5085(65)80041-5","volume":"48","author":"HG Hers","year":"1965","unstructured":"Hers HG (1965) Inborn lysosomal diseases. Gastroenterology 48:625\u2013633","journal-title":"Gastroenterology"},{"key":"9500_CR24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev.bi.60.070191.001353","volume":"60","author":"EF Neufeld","year":"1991","unstructured":"Neufeld EF (1991) Lysosomal storage diseases. Annu Rev Biochem 60:257\u2013280","journal-title":"Annu Rev Biochem"},{"key":"9500_CR25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2004.01.011","volume":"82","author":"T Lucke","year":"2004","unstructured":"Lucke T, Hoppner W, Schmidt E, Illsinger S, Das AM (2004) Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab 82:93\u201397","journal-title":"Mol Genet Metab"},{"key":"9500_CR26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijcard.2009.03.045","volume":"144","author":"T Palecek","year":"2010","unstructured":"Palecek T, Bultas J, Hajek M et al (2010) Association between cardiac energy metabolism and gain of left ventricular mass in Fabry disease. Int J Cardiol 144:337\u2013339","journal-title":"Int J Cardiol"},{"key":"9500_CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0065-2423(09)49003-6","volume":"49","author":"AM Das","year":"2009","unstructured":"Das AM, Naim HY (2009) Biochemical basis of Fabry disease with emphasis on mitochondrial function and protein trafficking. Adv Clin Chem 49:57\u201371","journal-title":"Adv Clin Chem"},{"key":"9500_CR28","doi-asserted-by":"crossref","first-page":"H1133","DOI":"10.1152\/ajpheart.00929.2008","volume":"296","author":"JL Park","year":"2009","unstructured":"Park JL, Shu L, Shayman JA (2009) Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse. Am J Physiol Heart Circ Physiol 296:H1133\u2013H1140","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9500_CR29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/cvr\/cvq333","volume":"89","author":"S Park","year":"2011","unstructured":"Park S, Kim JA, Joo KY et al (2011) Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease. Cardiovasc Res 89:290\u2013299","journal-title":"Cardiovasc Res"},{"key":"9500_CR30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","volume":"95","author":"JS Shen","year":"2008","unstructured":"Shen JS, Meng XL, Moore DF et al (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95:163\u2013168","journal-title":"Mol Genet Metab"},{"key":"9500_CR31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4161\/auto.6.5.11943","volume":"6","author":"M Chevrier","year":"2010","unstructured":"Chevrier M, Brakch N, Celine L et al (2010) Autophagosome maturation is impaired in Fabry disease. Autophagy 6:589\u2013599","journal-title":"Autophagy"},{"key":"9500_CR32","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","volume":"26","author":"F Weidemann","year":"2005","unstructured":"Weidemann F, Breunig F, Beer M et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221\u20131227","journal-title":"Eur Heart J"},{"key":"9500_CR33","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","volume":"97","author":"M Beer","year":"2006","unstructured":"Beer M, Weidemann F, Breunig F et al (2006) Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry\u2019s cardiomyopathy. Am J Cardiol 97:1515\u20131518","journal-title":"Am J Cardiol"},{"key":"9500_CR34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/10976640600605002","volume":"8","author":"JC Moon","year":"2006","unstructured":"Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ (2006) The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 8:479\u2013482","journal-title":"J Cardiovasc Magn Reson"},{"key":"9500_CR35","doi-asserted-by":"crossref","unstructured":"Torra R. Renal manifestations in Fabry disease and therapeutic options. Kidney Int Suppl 2008:S29\u2013S32","DOI":"10.1038\/ki.2008.522"},{"key":"9500_CR36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M et al (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res 64:550\u2013555","journal-title":"Pediatr Res"},{"key":"9500_CR37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab 93:112\u2013128","journal-title":"Mol Genet Metab"},{"key":"9500_CR38","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock DG, Banikazemi M et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102\u20132111","journal-title":"Nephrol Dial Transplant"},{"key":"9500_CR39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769\u2013775","journal-title":"J Med Genet"},{"key":"9500_CR40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","volume":"103","author":"A Mehta","year":"2010","unstructured":"Mehta A, Beck M, Eyskens F et al (2010) Fabry disease: a review of current management strategies. QJM 103:641\u2013659","journal-title":"QJM"},{"key":"9500_CR41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","volume":"417","author":"M Elleder","year":"1990","unstructured":"Elleder M, Bradova V, Smid F et al (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry\u2019s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417:449\u2013455","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"9500_CR42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med 333:288\u2013293","journal-title":"N Engl J Med"},{"key":"9500_CR43","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T et al (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int 64:801\u2013807","journal-title":"Kidney Int"},{"key":"9500_CR44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/08035320600618809","volume":"95","author":"EM Maier","year":"2006","unstructured":"Maier EM, Osterrieder S, Whybra C et al (2006) Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl 95:30\u201338","journal-title":"Acta Paediatr Suppl"},{"key":"9500_CR45","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1681\/ASN.2008020198","volume":"19","author":"BR Migeon","year":"2008","unstructured":"Migeon BR (2008) X inactivation, female mosaicism, and sex differences in renal diseases. J Am Soc Nephrol 19:2052\u20132059","journal-title":"J Am Soc Nephrol"},{"key":"9500_CR46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151\u2013156","journal-title":"Hum Genet"},{"key":"9500_CR47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249\u2013254","journal-title":"JAMA"},{"key":"9500_CR48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"9500_CR49","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC et al (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936\u00a0+\u00a0919G\u00a0>\u00a0A (IVS4\u00a0+\u00a0919G\u00a0>\u00a0A). Hum Mutat 30:1397\u20131405","journal-title":"Hum Mutat"},{"key":"9500_CR50","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Lin HY, Chong KW, Hsu JH et al (2009) High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet 2:450\u2013456","journal-title":"Circ Cardiovasc Genet"},{"key":"9500_CR51","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","volume":"24","author":"C Whybra","year":"2001","unstructured":"Whybra C, Kampmann C, Willers I et al (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24:715\u2013724","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR52","volume-title":"Fabry disease: perspectives from 5\u00a0years of FOS","author":"DP Germain","year":"2006","unstructured":"Germain DP (2006) General aspects of X-linked diseases. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5\u00a0years of FOS. Oxford PharmaGenesis, Oxford"},{"issue":"Suppl 2","key":"9500_CR53","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/S0248-8663(10)70013-8","volume":"31","author":"DP Germain","year":"2010","unstructured":"Germain DP, Benistan K, Angelova L (2010) X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease. Rev Med Interne 31(Suppl 2):S209\u2013S213","journal-title":"Rev Med Interne"},{"key":"9500_CR54","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1006\/bbrc.1993.2659","volume":"197","author":"S Ishii","year":"1993","unstructured":"Ishii S, Kase R, Sakuraba H, Suzuki Y (1993) Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun 197:1585\u20131589","journal-title":"Biochem Biophys Res Commun"},{"key":"9500_CR55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","volume":"406","author":"S Ishii","year":"2007","unstructured":"Ishii S, Chang HH, Kawasaki K et al (2007) Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 406:285\u2013295","journal-title":"Biochem J"},{"key":"9500_CR56","first-page":"784","volume":"47","author":"H Sakuraba","year":"1990","unstructured":"Sakuraba H, Oshima A, Fukuhara Y et al (1990) Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 47:784\u2013789","journal-title":"Am J Hum Genet"},{"key":"9500_CR57","first-page":"1186","volume":"53","author":"CM Eng","year":"1993","unstructured":"Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ (1993) Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53:1186\u20131197","journal-title":"Am J Hum Genet"},{"key":"9500_CR58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/humu.1380030204","volume":"3","author":"CM Eng","year":"1994","unstructured":"Eng CM, Desnick RJ (1994) Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum Mutat 3:103\u2013111","journal-title":"Hum Mutat"},{"key":"9500_CR59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/3.3.503","volume":"3","author":"JK Ploos van Amstel","year":"1994","unstructured":"Ploos van Amstel JK, Jansen RP, de Jong JG, Hamel BC, Wevers RA (1994) Six novel mutations in the alpha-galactosidase A gene in families with Fabry disease. Hum Mol Genet 3:503\u2013505","journal-title":"Hum Mol Genet"},{"key":"9500_CR60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/(SICI)1098-1004(1996)8:1<38::AID-HUMU5>3.0.CO;2-L","volume":"8","author":"LC Blanch","year":"1996","unstructured":"Blanch LC, Meaney C, Morris CP (1996) A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene. Hum Mutat 8:38\u201343","journal-title":"Hum Mutat"},{"key":"9500_CR61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000472202","volume":"4","author":"JP Davies","year":"1996","unstructured":"Davies JP, Eng CM, Hill JA et al (1996) Fabry disease: fourteen alpha-galactosidase A mutations in unrelated families from the United Kingdom and other European countries. Eur J Hum Genet 4:219\u2013224","journal-title":"Eur J Hum Genet"},{"key":"9500_CR62","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s004390050292","volume":"98","author":"D Germain","year":"1996","unstructured":"Germain D, Biasotto M, Tosi M, Meo T, Kahn A, Poenaru L (1996) Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease. Hum Genet 98:719\u2013726","journal-title":"Hum Genet"},{"key":"9500_CR63","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jmg.33.8.682","volume":"33","author":"I Redonnet-Vernhet","year":"1996","unstructured":"Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T (1996) Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet 33:682\u2013688","journal-title":"J Med Genet"},{"key":"9500_CR64","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","volume":"3","author":"CM Eng","year":"1997","unstructured":"Eng CM, Ashley GA, Burgert TS, Enriquez AL, D\u2019Souza M, Desnick RJ (1997) Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 3:174\u2013182","journal-title":"Mol Med"},{"key":"9500_CR65","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1002\/humu.1380110190","volume":"Suppl 1","author":"N Guffon","year":"1998","unstructured":"Guffon N, Froissart R, Chevalier-Porst F, Maire I (1998) Mutation analysis in 11 French patients with Fabry disease. Hum Mutat Suppl 1:S288\u2013S290","journal-title":"Hum Mutat"},{"key":"9500_CR66","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/bbrc.1999.0310","volume":"257","author":"DP Germain","year":"1999","unstructured":"Germain DP, Poenaru L (1999) Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. Biochem Biophys Res Commun 257:708\u2013713","journal-title":"Biochem Biophys Res Commun"},{"key":"9500_CR67","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/BF03401993","volume":"5","author":"AK Topaloglu","year":"1999","unstructured":"Topaloglu AK, Ashley GA, Tong B et al (1999) Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol Med 5:806\u2013811","journal-title":"Mol Med"},{"key":"9500_CR68","first-page":"227","volume":"48","author":"P Ashton-Prolla","year":"2000","unstructured":"Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ (2000) Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 48:227\u2013235","journal-title":"J Investig Med"},{"key":"9500_CR69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0925-4439(00)00024-7","volume":"1501","author":"R Kase","year":"2000","unstructured":"Kase R, Bierfreund U, Klein A et al (2000) Characterization of two alpha-galactosidase mutants (Q279E and R301Q) found in an atypical variant of Fabry disease. Biochim Biophys Acta 1501:227\u2013235","journal-title":"Biochim Biophys Acta"},{"key":"9500_CR70","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1034\/j.1399-0004.2000.580311.x","volume":"58","author":"JK Lee","year":"2000","unstructured":"Lee JK, Kim GH, Kim JS, Kim KK, Lee MC, Yoo HW (2000) Identification of four novel mutations in five unrelated Korean families with Fabry disease. Clin Genet 58:228\u2013233","journal-title":"Clin Genet"},{"key":"9500_CR71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2001.600107.x","volume":"60","author":"GM Altarescu","year":"2001","unstructured":"Altarescu GM, Goldfarb LG, Park KY et al (2001) Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 60:46\u201351","journal-title":"Clin Genet"},{"key":"9500_CR72","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s100380170088","volume":"46","author":"GA Ashley","year":"2001","unstructured":"Ashley GA, Shabbeer J, Yasuda M, Eng CM, Desnick RJ (2001) Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype. J Hum Genet 46:192\u2013196","journal-title":"J Hum Genet"},{"key":"9500_CR73","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/humu.1219","volume":"18","author":"D Blaydon","year":"2001","unstructured":"Blaydon D, Hill J, Winchester B (2001) Fabry disease: 20 novel GLA mutations in 35 families. Hum Mutat 18:459","journal-title":"Hum Mutat"},{"key":"9500_CR74","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/humu.41","volume":"17","author":"DP Germain","year":"2001","unstructured":"Germain DP, Salard D, Fellmann F et al (2001) Identification of a novel de novo mutation (G373D) in the alpha-galactosidase A gene (GLA) in a patient affected with Fabry disease. Hum Mutat 17:353","journal-title":"Hum Mutat"},{"key":"9500_CR75","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1034\/j.1399-0004.2001.600110.x","volume":"60","author":"DP Germain","year":"2001","unstructured":"Germain DP (2001) Co-occurrence and contribution of Fabry disease and Klippel-Trenaunay-Weber syndrome to a patient with atypical skin lesions. Clin Genet 60:63\u201367","journal-title":"Clin Genet"},{"key":"9500_CR76","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF03402156","volume":"8","author":"DP Germain","year":"2002","unstructured":"Germain DP, Shabbeer J, Cotigny S, Desnick RJ (2002) Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes. Mol Med 8:306\u2013312","journal-title":"Mol Med"},{"key":"9500_CR77","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/376608","volume":"73","author":"M Yasuda","year":"2003","unstructured":"Yasuda M, Shabbeer J, Osawa M, Desnick RJ (2003) Fabry disease: novel alpha-galactosidase A 3\u2032-terminal mutations result in multiple transcripts due to aberrant 3\u2032-end formation. Am J Hum Genet 73:162\u2013173","journal-title":"Am J Hum Genet"},{"key":"9500_CR78","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","volume":"337","author":"SC Garman","year":"2004","unstructured":"Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337:319\u2013335","journal-title":"J Mol Biol"},{"key":"9500_CR79","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajmg.a.30533","volume":"134A","author":"R Dobrovolny","year":"2005","unstructured":"Dobrovolny R, Dvorakova L, Ledvinova J et al (2005) Recurrence of Fabry disease as a result of paternal germline mosaicism for alpha-galactosidase a gene mutation. Am J Med Genet A 134A:84\u201387","journal-title":"Am J Med Genet A"},{"key":"9500_CR80","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/humu.20144","volume":"25","author":"J Shabbeer","year":"2005","unstructured":"Shabbeer J, Robinson M, Desnick RJ (2005) Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography. Hum Mutat 25:299\u2013305","journal-title":"Hum Mutat"},{"key":"9500_CR81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/08035320510031045","volume":"94","author":"E Schaefer","year":"2005","unstructured":"Schaefer E, Mehta A, Gal A (2005) Genotype and phenotype in Fabry disease: analysis of the Fabry outcome survey. Acta Paediatr Suppl 94:87\u201392","journal-title":"Acta Paediatr Suppl"},{"key":"9500_CR82","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","volume":"2","author":"J Shabbeer","year":"2006","unstructured":"Shabbeer J, Yasuda M, Benson SD, Desnick RJ (2006) Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genomics 2:297\u2013309","journal-title":"Hum Genomics"},{"key":"9500_CR83","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/humu.9520","volume":"29","author":"M Shimotori","year":"2008","unstructured":"Shimotori M, Maruyama H, Nakamura G et al (2008) Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum Mutat 29:331","journal-title":"Hum Mutat"},{"key":"9500_CR84","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI114027","volume":"83","author":"HS Bernstein","year":"1989","unstructured":"Bernstein HS, Bishop DF, Astrin KH et al (1989) Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest 83:1390\u20131399","journal-title":"J Clin Invest"},{"key":"9500_CR85","doi-asserted-by":"crossref","first-page":"9319","DOI":"10.1016\/S0021-9258(19)38851-9","volume":"265","author":"R Kornreich","year":"1990","unstructured":"Kornreich R, Bishop DF, Desnick RJ (1990) Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene. J Biol Chem 265:9319\u20139326","journal-title":"J Biol Chem"},{"key":"9500_CR86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-90-481-9033-1_1","volume-title":"Fabry disease","author":"A Gal","year":"2010","unstructured":"Gal A (2010) Molecular genetics of Fabry disease and genotype-phenotype correlation. In: Elstein D, Altarescu G, Beck M (eds) Fabry disease. Springer, Dordrecht, Heidelberg, London, pp 3\u201319"},{"key":"9500_CR87","unstructured":"The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff"},{"key":"9500_CR88","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","volume":"80","author":"R Froissart","year":"2003","unstructured":"Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80:307\u2013314","journal-title":"Mol Genet Metab"},{"key":"9500_CR89","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/jmg.30.8.658","volume":"30","author":"JP Davies","year":"1993","unstructured":"Davies JP, Winchester BG, Malcolm S (1993) Sequence variations in the first exon of alpha-galactosidase A. J Med Genet 30:658\u2013663","journal-title":"J Med Genet"},{"key":"9500_CR90","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1023\/A:1005366224351","volume":"20","author":"TF Fitzmaurice","year":"1997","unstructured":"Fitzmaurice TF, Desnick RJ, Bishop DF (1997) Human alpha-galactosidase A: high plasma activity expressed by the -30G\u2013\u00a0>\u00a0A allele. J Inherit Metab Dis 20:643\u2013657","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR91","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812\u20132817","journal-title":"Proc Natl Acad Sci USA"},{"key":"9500_CR92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-90-481-9033-1_2","volume-title":"The structure of human \u03b1-galactosidase A and implications for Fabry disease","author":"AI Guce","year":"2010","unstructured":"Guce AI (2010) The structure of human \u03b1-galactosidase A and implications for Fabry disease. Springe, Berlin, pp 21\u201338"},{"key":"9500_CR93","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1074\/jbc.M109.060145","volume":"285","author":"AI Guce","year":"2010","unstructured":"Guce AI, Clark NE, Salgado EN et al (2010) Catalytic mechanism of human alpha-galactosidase. J Biol Chem 285:3625\u20133632","journal-title":"J Biol Chem"},{"key":"9500_CR94","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00004691-200212000-00011","volume":"19","author":"M Dutsch","year":"2002","unstructured":"Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ (2002) Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 19:575\u2013586","journal-title":"J Clin Neurophysiol"},{"key":"9500_CR95","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.32.5.498","volume":"32","author":"WJ Cable","year":"1982","unstructured":"Cable WJ, Kolodny EH, Adams RD (1982) Fabry disease: impaired autonomic function. Neurology 32:498\u2013502","journal-title":"Neurology"},{"key":"9500_CR96","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami U, Whybra C, Parini R et al (2006) Clinical manifestations of Fabry disease in children: data from the Fabry outcome survey. Acta Paediatr 95:86\u201392","journal-title":"Acta Paediatr"},{"key":"9500_CR97","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","volume":"144","author":"RJ Desnick","year":"2004","unstructured":"Desnick RJ, Brady RO (2004) Fabry disease in childhood. J Pediatr 144:S20\u2013S26","journal-title":"J Pediatr"},{"key":"9500_CR98","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ (2008) Fabry\u2019s disease. Lancet 372:1427\u20131435","journal-title":"Lancet"},{"key":"9500_CR99","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","volume":"23","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2014a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23:535\u2013542","journal-title":"Clin J Pain"},{"issue":"190","key":"9500_CR100","first-page":"192","volume":"38","author":"J Charrow","year":"2009","unstructured":"Charrow J (2009) A 14-year-old boy with pain in hands and feet. Pediatr Ann 38(190):192","journal-title":"Pediatr Ann"},{"key":"9500_CR101","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0304-3959(99)00236-5","volume":"84","author":"MJ Hilz","year":"2000","unstructured":"Hilz MJ, Stemper B, Kolodny EH (2000) Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 84:361\u2013365","journal-title":"Pain"},{"key":"9500_CR102","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pain.2009.07.025","volume":"145","author":"D Naleschinski","year":"2009","unstructured":"Naleschinski D, Arning K, Baron R (2009) Fabry disease\u2013pain doctors have to find the missing ones. Pain 145:10\u201311","journal-title":"Pain"},{"key":"9500_CR103","first-page":"246","volume":"76","author":"KJ Sheth","year":"1981","unstructured":"Sheth KJ, Werlin SL, Freeman ME, Hodach AE (1981) Gastrointestinal structure and function in Fabry\u2019s disease. Am J Gastroenterol 76:246\u2013251","journal-title":"Am J Gastroenterol"},{"key":"9500_CR104","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S (2007) Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5:1447\u20131453","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9500_CR105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539\u2013548","journal-title":"Genet Med"},{"key":"9500_CR106","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0190-9622(87)70274-6","volume":"17","author":"WH Kang","year":"1987","unstructured":"Kang WH, Chun SI, Lee S (1987) Generalized anhidrosis associated with Fabry\u2019s disease. J Am Acad Dermatol 17:883\u2013887","journal-title":"J Am Acad Dermatol"},{"key":"9500_CR107","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","volume":"157","author":"CH Orteu","year":"2007","unstructured":"Orteu CH, Jansen T, Lidove O et al (2007) Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 157:331\u2013337","journal-title":"Br J Dermatol"},{"key":"9500_CR108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2377-8-41","volume":"8","author":"SN Gupta","year":"2008","unstructured":"Gupta SN, Ries M, Murray GJ et al (2008) Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study. BMC Neurol 8:41","journal-title":"BMC Neurol"},{"key":"9500_CR109","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1525-1470.1995.tb00161.x","volume":"12","author":"ED Shelley","year":"1995","unstructured":"Shelley ED, Shelley WB, Kurczynski TW (1995) Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. Pediatr Dermatol 12:215\u2013219","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"9500_CR110","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1051\/jbio\/2002196020161","volume":"196","author":"DP Germain","year":"2002","unstructured":"Germain DP (2002) Fabry\u2019s disease (alpha-galactosidase-A deficiency): physiopathology, clinical signs, and genetic aspects. J Soc Biol 196(2):161\u2013173","journal-title":"J Soc Biol"},{"key":"9500_CR111","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00128071-200304030-00005","volume":"4","author":"M Mohrenschlager","year":"2003","unstructured":"Mohrenschlager M, Braun-Falco M, Ring J, Abeck D (2003) Fabry disease: recognition and management of cutaneous manifestations. Am J Clin Dermatol 4:189\u2013196","journal-title":"Am J Clin Dermatol"},{"key":"9500_CR112","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10545-009-1290-x","volume":"32","author":"A Keilmann","year":"2009","unstructured":"Keilmann A, Hajioff D, Ramaswami U (2009) Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey. J Inherit Metab Dis 32:739\u2013744","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR113","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","volume":"115","author":"M Ries","year":"2005","unstructured":"Ries M, Gupta S, Moore DF et al (2005) Pediatric Fabry disease. Pediatrics 115:e344\u2013e355","journal-title":"Pediatrics"},{"key":"9500_CR114","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1651-2227.2008.00700.x","volume":"97","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463\u2013469","journal-title":"Acta Paediatr"},{"key":"9500_CR115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpeds.2005.03.004","volume":"147","author":"MA Cabrera-Salazar","year":"2005","unstructured":"Cabrera-Salazar MA, O\u2019Rourke E, Charria-Ortiz G, Barranger JA (2005) Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. J Pediatr 147:102\u2013105","journal-title":"J Pediatr"},{"key":"9500_CR116","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","volume":"13","author":"MC Gubler","year":"1978","unstructured":"Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R (1978) Early renal changes in hemizygous and heterozygous patients with Fabry\u2019s disease. Kidney Int 13:223\u2013235","journal-title":"Kidney Int"},{"key":"9500_CR117","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","volume":"25","author":"AB Fogo","year":"2010","unstructured":"Fogo AB, Bostad L, Svarstad E et al (2010) Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 25:2168\u20132177","journal-title":"Nephrol Dial Transplant"},{"key":"9500_CR118","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","volume":"51","author":"C Tondel","year":"2008","unstructured":"Tondel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51:767\u2013776","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 2","key":"9500_CR119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1023\/A:1012423924648","volume":"24","author":"A Sessa","year":"2001","unstructured":"Sessa A, Meroni M, Battini G et al (2001) Renal pathological changes in Fabry disease. J Inherit Metab Dis 24(Suppl 2):66\u201370","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR120","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/sj.ki.5002677","volume":"73","author":"FC Fervenza","year":"2008","unstructured":"Fervenza FC, Torra R, Lager DJ (2008) Fabry disease: an underrecognized cause of proteinuria. Kidney Int 73:1193\u20131199","journal-title":"Kidney Int"},{"key":"9500_CR121","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","volume":"23","author":"A Ortiz","year":"2008","unstructured":"Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23:1600\u20131607","journal-title":"Nephrol Dial Transplant"},{"key":"9500_CR122","first-page":"660","volume":"138","author":"H Hulkova","year":"1999","unstructured":"Hulkova H, Ledvinova J, Poupetova H, Bultas J, Zeman J (1999) Elleder M [Postmortem diagnosis of Fabry disease in a female heterozygote leading to the detection of undiagnosed manifest disease in the family]. Cas Lek Cesk 138:660\u2013664","journal-title":"Cas Lek Cesk"},{"key":"9500_CR123","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","volume":"19","author":"H Ashrafian","year":"2003","unstructured":"Ashrafian H, Redwood C, Blair E, Watkins H (2003) Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet 19:263\u2013268","journal-title":"Trends Genet"},{"key":"9500_CR124","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1161\/01.CIR.97.25.2536","volume":"97","author":"WI Jung","year":"1998","unstructured":"Jung WI, Sieverding L, Breuer J et al (1998) 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97:2536\u20132542","journal-title":"Circulation"},{"key":"9500_CR125","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","volume":"139","author":"A Linhart","year":"2000","unstructured":"Linhart A, Palecek T, Bultas J et al (2000) New insights in cardiac structural changes in patients with Fabry\u2019s disease. Am Heart J 139:1101\u20131108","journal-title":"Am Heart J"},{"key":"9500_CR126","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","volume":"40","author":"C Kampmann","year":"2002","unstructured":"Kampmann C, Baehner F, Whybra C et al (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40:1668\u20131674","journal-title":"J Am Coll Cardiol"},{"key":"9500_CR127","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","volume":"63","author":"M Senechal","year":"2003","unstructured":"Senechal M, Germain DP (2003) Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 63:46\u201352","journal-title":"Clin Genet"},{"key":"9500_CR128","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","volume":"96","author":"JS Shah","year":"2005","unstructured":"Shah JS, Hughes DA, Sachdev B et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96:842\u2013846","journal-title":"Am J Cardiol"},{"key":"9500_CR129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/hrt.2004.054015","volume":"92","author":"PM Elliott","year":"2006","unstructured":"Elliott PM, Kindler H, Shah JS et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357\u2013360","journal-title":"Heart"},{"key":"9500_CR130","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1161\/CIRCULATIONAHA.105.584292","volume":"113","author":"H Hasegawa","year":"2006","unstructured":"Hasegawa H, Takano H, Shindo S et al (2006) Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease. Circulation 113:e720\u2013e721","journal-title":"Circulation"},{"key":"9500_CR131","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228\u20131235","journal-title":"Eur Heart J"},{"key":"9500_CR132","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","volume":"130","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Linhart A, Baehner F et al (2008) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130:367\u2013373","journal-title":"Int J Cardiol"},{"key":"9500_CR133","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","volume":"51","author":"T Takenaka","year":"2008","unstructured":"Takenaka T, Teraguchi H, Yoshida A et al (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51:50\u201359","journal-title":"J Cardiol"},{"key":"9500_CR134","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JT, Giugliani R et al (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014fabry outcome survey. J Med Genet 46:548\u2013552","journal-title":"J Med Genet"},{"key":"9500_CR135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","volume":"28","author":"RJ Kalliokoski","year":"2005","unstructured":"Kalliokoski RJ, Kalliokoski KK, Sundell J et al (2005) Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 28:563\u2013573","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR136","first-page":"300","volume":"81","author":"DP Germain","year":"2007","unstructured":"Germain DP (2007) Aortic root dilatation is highly prevalent in male patients affected with Fabry disease and correlates with the presence of a megadolicho-ectatic basilar artery. Am J Hum Genet 81:300","journal-title":"Am J Hum Genet"},{"key":"9500_CR137","first-page":"471","volume":"136","author":"U Glockel","year":"1988","unstructured":"Glockel U, Schwenk HU (1988) Beck JD [Successful combination therapy of a metastatic Triton tumor in a 5-year-old boy]. Monatsschr Kinderheilkd 136:471\u2013474","journal-title":"Monatsschr Kinderheilkd"},{"key":"9500_CR138","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1093\/eurheartj\/ehr242","volume":"32","author":"P Ruggenenti","year":"2011","unstructured":"Ruggenenti P, Remuzzi G (2011) Worsening kidney function in decompensated heart failure: treat the heart, don\u2019t mind the kidney. Eur Heart J 32:2476\u20132478","journal-title":"Eur Heart J"},{"key":"9500_CR139","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00041552-200403000-00004","volume":"13","author":"D Silverberg","year":"2004","unstructured":"Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A (2004) The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 13:163\u2013170","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"9500_CR140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/0284185195036S39912","volume":"399","author":"TW Morris","year":"1995","unstructured":"Morris TW (1995) A review of coronary arteriography- and contrast media-induced ventricular fibrillation. Acta Radiol Suppl 399:100\u2013104","journal-title":"Acta Radiol Suppl"},{"key":"9500_CR141","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ki.5000368","volume":"69","author":"R Mehran","year":"2006","unstructured":"Mehran R, Nikolsky E (2006) Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 69:S11\u2013S15","journal-title":"Kidney Int Suppl"},{"key":"9500_CR142","first-page":"266","volume":"32","author":"M Arakawa","year":"1992","unstructured":"Arakawa M (1992) NSAID induced-nephropathy. Ryumachi 32:266\u2013269","journal-title":"Ryumachi"},{"key":"9500_CR143","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0303-8467(78)80006-7","volume":"80","author":"AJ Veuger","year":"1977","unstructured":"Veuger AJ, Kortbeek LH, Booij AC (1977) Siderophages in differentiation of blood in cerebrospinal fluid. Clin Neurol Neurosurg 80:46\u201356","journal-title":"Clin Neurol Neurosurg"},{"key":"9500_CR144","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1097\/CCM.0b013e318168e333","volume":"36","author":"L Maerz","year":"2008","unstructured":"Maerz L, Kaplan LJ (2008) Abdominal compartment syndrome. Crit Care Med 36:S212\u2013S215","journal-title":"Crit Care Med"},{"key":"9500_CR145","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2133.2004.05813.x","volume":"150","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, De Rie MA, Tjiam KH, Aerts JM, Dingemans KP, Hollak CE (2004) Misdiagnosis of Fabry disease: importance of biochemical confirmation of clinical or pathological suspicion. Br J Dermatol 150:575\u2013577","journal-title":"Br J Dermatol"},{"key":"9500_CR146","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","volume":"112","author":"JS Mayes","year":"1981","unstructured":"Mayes JS, Scheerer JB, Sifers RN, Donaldson ML (1981) Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry\u2019s disease. Clin Chim Acta 112:247\u2013251","journal-title":"Clin Chim Acta"},{"key":"9500_CR147","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1515\/CCLM.2005.219","volume":"43","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann B, Georg Koch H, Schweitzer-Krantz S, Wendel U, Mayatepek E (2005) Deficient alpha-galactosidase A activity in plasma but no Fabry disease\u2013a pitfall in diagnosis. Clin Chem Lab Med 43:1276\u20131277","journal-title":"Clin Chem Lab Med"},{"key":"9500_CR148","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","volume":"353","author":"GE Linthorst","year":"2005","unstructured":"Linthorst GE, Vedder AC, Aerts JM, Hollak CE (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353:201\u2013203","journal-title":"Clin Chim Acta"},{"key":"9500_CR149","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","volume":"308","author":"NA Chamoles","year":"2001","unstructured":"Chamoles NA, Blanco M, Gaggioli D (2001) Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 308:195\u2013196","journal-title":"Clin Chim Acta"},{"key":"9500_CR150","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1051\/medsci\/20052111s48","volume":"21","author":"E Caudron","year":"2005","unstructured":"Caudron E, Moliere D, Zhou JY, Prognon P, Germain DP (2005) Recent advances of Fabry disease screening for at risk population. Med Sci (Paris) 21:48\u201350","journal-title":"Med Sci (Paris)"},{"key":"9500_CR151","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10545-005-0039-4","volume":"28","author":"Z Lukacs","year":"2005","unstructured":"Lukacs Z, Keil A, Kohlschutter A, Beck M, Mengel E (2005) The ratio of alpha-galactosidase to beta-glucuronidase activities in dried blood for the identification of female Fabry disease patients. J Inherit Metab Dis 28:803\u2013805","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR152","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1373\/clinchem.2008.104711","volume":"54","author":"XK Zhang","year":"2008","unstructured":"Zhang XK, Elbin CS, Chuang WL et al (2008) Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem 54:1725\u20131728","journal-title":"Clin Chem"},{"key":"9500_CR153","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cca.2009.02.008","volume":"403","author":"P Olivova","year":"2009","unstructured":"Olivova P, van der Veen K, Cullen E et al (2009) Effect of sample collection on alpha-galactosidase A enzyme activity measurements in dried blood spots on filter paper. Clin Chim Acta 403:159\u2013162","journal-title":"Clin Chim Acta"},{"key":"9500_CR154","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","volume":"30","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, van Breemen MJ et al (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68\u201378","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jchromb.2004.03.037","volume":"805","author":"S Roy","year":"2004","unstructured":"Roy S, Gaudin K, Germain DP, Baillet A, Prognon P, Chaminade P (2004) Optimisation of the separation of four major neutral glycosphingolipids: application to a rapid and simple detection of urinary globotriaosylceramide in Fabry disease. J Chromatogr B Analyt Technol Biomed Life Sci 805:331\u2013337","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"9500_CR156","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","volume":"30","author":"C Auray-Blais","year":"2007","unstructured":"Auray-Blais C, Cyr D, Mills K, Giguere R, Drouin R (2007) Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. J Inherit Metab Dis 30:106","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR157","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","volume":"93","author":"C Auray-Blais","year":"2008","unstructured":"Auray-Blais C, Cyr D, Ntwari A et al (2008) Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 93:331\u2013340","journal-title":"Mol Genet Metab"},{"key":"9500_CR158","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00216-005-3239-8","volume":"382","author":"D Touboul","year":"2005","unstructured":"Touboul D, Roy S, Germain DP et al (2005) Fast fingerprinting by MALDI-TOF mass spectrometry of urinary sediment glycosphingolipids in Fabry disease. Anal Bioanal Chem 382:1209\u20131216","journal-title":"Anal Bioanal Chem"},{"key":"9500_CR159","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","volume":"28","author":"K Mills","year":"2005","unstructured":"Mills K, Morris P, Lee P et al (2005) Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J Inherit Metab Dis 28:35\u201348","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","volume":"94","author":"E Young","year":"2005","unstructured":"Young E, Mills K, Morris P et al (2005) Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 94:51\u201354","journal-title":"Acta Paediatr Suppl"},{"key":"9500_CR161","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1051\/medsci\/20052111s45","volume":"21","author":"M Piraud","year":"2005","unstructured":"Piraud M, de Goiffon F, Froissart R, Maire I, Vanier MT (2005) Globotriaosylceramide measurement in urine. Med Sci (Paris) 21:45\u201347","journal-title":"Med Sci (Paris)"},{"key":"9500_CR162","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1073\/pnas.83.13.4859","volume":"83","author":"DF Bishop","year":"1986","unstructured":"Bishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ (1986) Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci USA 83:4859\u20134863","journal-title":"Proc Natl Acad Sci USA"},{"key":"9500_CR163","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1093\/nar\/17.8.3301","volume":"17","author":"R Kornreich","year":"1989","unstructured":"Kornreich R, Desnick RJ, Bishop DF (1989) Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res 17:3301\u20133302","journal-title":"Nucleic Acids Res"},{"key":"9500_CR164","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/humu.9172","volume":"22","author":"A Rodriguez-Mari","year":"2003","unstructured":"Rodriguez-Mari A, Coll MJ, Chabas A (2003) Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat 22:258","journal-title":"Hum Mutat"},{"key":"9500_CR165","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ymgme.2008.03.017","volume":"94","author":"A Schirinzi","year":"2008","unstructured":"Schirinzi A, Centra M, Prattichizzo C et al (2008) Identification of GLA gene deletions in Fabry patients by Multiplex Ligation-dependent Probe Amplification (MLPA). Mol Genet Metab 94:382\u2013385","journal-title":"Mol Genet Metab"},{"key":"9500_CR166","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/187152506778520718","volume":"4","author":"S Bekri","year":"2006","unstructured":"Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F (2006) The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 4:289\u2013297","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"9500_CR167","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2215\/CJN.02490607","volume":"3","author":"J Andrade","year":"2008","unstructured":"Andrade J, Waters PJ, Singh RS et al (2008) Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol 3:139\u2013145","journal-title":"Clin J Am Soc Nephrol"},{"key":"9500_CR168","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.clineuro.2007.03.008","volume":"109","author":"R Brouns","year":"2007","unstructured":"Brouns R, Sheorajpanday R, Braxel E et al (2007) Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 109:479\u2013484","journal-title":"Clin Neurol Neurosurg"},{"key":"9500_CR169","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2004.035907","volume":"50","author":"Y Li","year":"2004","unstructured":"Li Y, Scott CR, Chamoles NA et al (2004) Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50:1785\u20131796","journal-title":"Clin Chem"},{"key":"9500_CR170","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10545-006-0265-4","volume":"29","author":"MH Gelb","year":"2006","unstructured":"Gelb MH, Turecek F, Scott CR, Chamoles NA (2006) Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 29:397\u2013404","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR171","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00401-005-0026-8","volume":"111","author":"C Navarro","year":"2006","unstructured":"Navarro C, Teijeira S, Dominguez C et al (2006) Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients. Acta Neuropathol 111:178\u2013185","journal-title":"Acta Neuropathol"},{"key":"9500_CR172","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/modpathol.3800344","volume":"18","author":"D Albay","year":"2005","unstructured":"Albay D, Adler SG, Philipose J, Calescibetta CC, Romansky SG, Cohen AH (2005) Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol 18:733\u2013738","journal-title":"Mod Pathol"},{"key":"9500_CR173","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1523-1755.2005.00294.x","volume":"67","author":"J Kleinert","year":"2005","unstructured":"Kleinert J, Dehout F, Schwarting A et al (2005) Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey. Kidney Int 67:1955\u20131960","journal-title":"Kidney Int"},{"key":"9500_CR174","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1651-2227.2002.tb03112.x","volume":"91","author":"K Demuth","year":"2002","unstructured":"Demuth K, Germain DP (2002) Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl 91:57\u201361","journal-title":"Acta Paediatr Suppl"},{"key":"9500_CR175","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1023\/B:BOLI.0000045841.27968.06","volume":"27","author":"DJ Cartwright","year":"2004","unstructured":"Cartwright DJ, Cole AL, Cousins AJ, Lee PJ (2004) Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy. J Inherit Metab Dis 27:791\u2013793","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR176","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ymgme.2006.04.013","volume":"89","author":"AC Vedder","year":"2006","unstructured":"Vedder AC, Cox-Brinkman J, Hollak CE et al (2006) Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol Genet Metab 89:239\u2013244","journal-title":"Mol Genet Metab"},{"key":"9500_CR177","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","volume":"1812","author":"MJ Breemen van","year":"2011","unstructured":"van Breemen MJ, Rombach SM, Dekker N et al (2011) Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812:70\u201376","journal-title":"Biochim Biophys Acta"},{"key":"9500_CR178","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG et al (2010) Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802:741\u2013748","journal-title":"Biochim Biophys Acta"},{"key":"9500_CR179","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","volume":"100","author":"T Togawa","year":"2010","unstructured":"Togawa T, Kodama T, Suzuki T et al (2010) Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab 100:257\u2013261","journal-title":"Mol Genet Metab"},{"key":"9500_CR180","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","volume":"411","author":"C Auray-Blais","year":"2010","unstructured":"Auray-Blais C, Ntwari A, Clarke JT et al (2010) How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta 411:1906\u20131914","journal-title":"Clin Chim Acta"},{"key":"9500_CR181","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","volume":"26","author":"MD Sanchez-Nino","year":"2011","unstructured":"Sanchez-Nino MD, Sanz AB, Carrasco S et al (2011) Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 26:1797\u20131802","journal-title":"Nephrol Dial Transplant"},{"key":"9500_CR182","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","volume":"31","author":"N Brakch","year":"2010","unstructured":"Brakch N (2010) Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J 31:67\u201376","journal-title":"Eur Heart J"},{"key":"9500_CR183","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/pd.1767","volume":"27","author":"RJ Desnick","year":"2007","unstructured":"Desnick RJ (2007) Prenatal diagnosis of Fabry disease. Prenat Diagn 27:693\u2013694","journal-title":"Prenat Diagn"},{"key":"9500_CR184","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00041552-200503000-00002","volume":"14","author":"DG Warnock","year":"2005","unstructured":"Warnock DG (2005) Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 14:87\u201395","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"9500_CR185","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0248-8663(00)00269-1","volume":"21","author":"DP Germain","year":"2000","unstructured":"Germain DP (2000) Fabry disease. Clinical and genetic aspects. Therapeutic perspectives. Rev Med Interne 21:1086\u20131103","journal-title":"Rev Med Interne"},{"key":"9500_CR186","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54\u00a0months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547\u20131557","journal-title":"J Am Soc Nephrol"},{"key":"9500_CR187","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1681\/ASN.2007070783","volume":"18","author":"C Wanner","year":"2007","unstructured":"Wanner C, Breunig F (2007) Fabry nephropathy and the case for adjunctive renal therapy. J Am Soc Nephrol 18:2426\u20132428","journal-title":"J Am Soc Nephrol"},{"key":"9500_CR188","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2215\/CJN.08191109","volume":"5","author":"DG Warnock","year":"2010","unstructured":"Warnock DG, Remuzzi G, Brenner BM, Levin A, Wanner C (2010) Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity. Clin J Am Soc Nephrol 5:359","journal-title":"Clin J Am Soc Nephrol"},{"key":"9500_CR189","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","volume":"19","author":"J Kleinert","year":"2006","unstructured":"Kleinert J, Dehout F, Schwarting A et al (2006) Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 19:782\u2013787","journal-title":"Am J Hypertens"},{"key":"9500_CR190","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","volume":"61","author":"R Thadhani","year":"2002","unstructured":"Thadhani R, Wolf M, West ML et al (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249\u2013255","journal-title":"Kidney Int"},{"key":"9500_CR191","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/ndt\/gfm813","volume":"23","author":"R Mignani","year":"2008","unstructured":"Mignani R, Feriozzi S, Pisani A et al (2008) Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 23:1628\u20131635","journal-title":"Nephrol Dial Transplant"},{"key":"9500_CR192","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1432-2277.2008.00824.x","volume":"22","author":"M Cybulla","year":"2009","unstructured":"Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G (2009) Kidney transplantation in patients with Fabry disease. Transpl Int 22:475\u2013481","journal-title":"Transpl Int"},{"key":"9500_CR193","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","volume":"69","author":"A Ojo","year":"2000","unstructured":"Ojo A, Meier-Kriesche HU, Friedman G et al (2000) Excellent outcome of renal transplantation in patients with Fabry\u2019s disease. Transplantation 69:2337\u20132339","journal-title":"Transplantation"},{"key":"9500_CR194","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/TP.0b013e318191a842","volume":"87","author":"T Shah","year":"2009","unstructured":"Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S (2009) Kidney transplant outcomes in patients with Fabry disease. Transplantation 87:280\u2013285","journal-title":"Transplantation"},{"key":"9500_CR195","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10545-009-1156-2","volume":"32","author":"JM Politei","year":"2009","unstructured":"Politei JM (2009) Can we use statins to prevent stroke in Fabry disease? J Inherit Metab Dis 32:481\u2013487","journal-title":"J Inherit Metab Dis"},{"key":"9500_CR196","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","volume":"93","author":"A Linhart","year":"2007","unstructured":"Linhart A, Elliott PM (2007) The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 93:528\u2013535","journal-title":"Heart"},{"key":"9500_CR197","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","volume":"13","author":"K Lee","year":"2003","unstructured":"Lee K, Jin X, Zhang K et al (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13:305\u2013313","journal-title":"Glycobiology"},{"key":"9500_CR198","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","volume":"51","author":"H Sakuraba","year":"2006","unstructured":"Sakuraba H, Murata-Ohsawa M, Kawashima I et al (2006) Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 51:180\u2013188","journal-title":"J Hum Genet"},{"key":"9500_CR199","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"key":"9500_CR200","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153\u2013158","journal-title":"Heart"},{"key":"9500_CR201","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345\u2013354","journal-title":"Nephrol Dial Transplant"},{"key":"9500_CR202","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet 374:1986\u20131996","journal-title":"Lancet"},{"key":"9500_CR203","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","volume":"118","author":"M Ries","year":"2006","unstructured":"Ries M, Clarke JT, Whybra C et al (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924\u2013932","journal-title":"Pediatrics"},{"key":"9500_CR204","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Martin RA, Reimschisel T et al (2010) Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 156:832\u20138327, 837 e1","DOI":"10.1016\/j.jpeds.2009.11.007"},{"key":"9500_CR205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry\u2019s disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"9500_CR206","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB et al (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933\u20131946","journal-title":"Kidney Int"},{"key":"9500_CR207","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77\u201386","journal-title":"Ann Intern Med"},{"key":"9500_CR208","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","volume":"119","author":"BL Thurberg","year":"2009","unstructured":"Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O\u2019Callaghan MW (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119:2561\u20132567","journal-title":"Circulation"},{"key":"9500_CR209","doi-asserted-by":"crossref","unstructured":"Wraith JE, Tylki-Szymanska A, Guffon N et al (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152:563\u2013570, 570 e1","DOI":"10.1016\/j.jpeds.2007.09.007"},{"key":"9500_CR210","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/13543784.11.10.1467","volume":"11","author":"DP Germain","year":"2002","unstructured":"Germain DP (2002) Fabry disease: recent advances in enzyme replacement therapy. Expert Opin Investig Drugs 11:1467\u20131476","journal-title":"Expert Opin Investig Drugs"},{"key":"9500_CR211","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","volume":"10","author":"D Bodensteiner","year":"2008","unstructured":"Bodensteiner D, Scott CR, Sims KB, Shepherd GM, Cintron RD, Germain DP (2008) Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med 10:353\u2013358","journal-title":"Genet Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-015-9500-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-015-9500-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-015-9500-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T19:35:08Z","timestamp":1652988908000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-015-9500-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,1]]},"references-count":211,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["9500"],"URL":"https:\/\/doi.org\/10.1007\/s10741-015-9500-0","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,1]]}}}